Product Description
TOT Biopharma are developing TAB-008, an intravenous drug candidate for the treatment of EGFR Wild-type Non-squamous Non-small Cell Lung Cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05427305?term=TAB-008&draw=2&rank=1)
Mechanisms of Action: VEGF Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Capital Medical University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR-IIR-16009827 |
ChiCTR-IIR-16009827 | N/A |
Recruiting |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2017-11-30 |
|||
CTR20170244 |
CTR20170244 | P3 |
Completed |
Non-Small-Cell Lung Cancer |
2020-03-24 |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT05427305 |
TOT-CR-TAB008-Ⅲ-01 | P3 |
Completed |
Non-Small-Cell Lung Cancer |
2020-03-24 |
2022-06-23 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/01/2021 |
News Article |
TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China |
|
04/21/2020 |
News Article |
TOT BIOPHARM Self-Developed Biological Drug TAB008 (Pusintin) Meets Primary Endpoint in Phase III Clinical Trial |
|
11/07/2019 |
News Article |
TOT BIOPHARM (1875.HK) Proceeded with IPO raising over HK$500 million |